For instance, a pan-HLA class II-restricted EBV peptide cocktail (derived from LMP1/LMP2/EBNA1) targeting EBV latency II-associated malignancies (such as Hodgkin’s lymphoma and NPC) has been shown to activate CD4+ T cell responses, offering a potential vaccine strategy against EBV-associated malignant tumors. Here, PDLIM7 is linked to cancer.